Endonovo Therapeutics Inc ENDV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENDV is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.02
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $838,546.46
- Volume/Avg
- 260,000 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.endonovo.com
Valuation
|
Metric
|
ENDV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 11.74 |
Price/Cash Flow | — |
Price/Earnings
ENDV
Financial Strength
|
Metric
|
ENDV
|
|---|---|
Quick Ratio | — |
Current Ratio | 0.00 |
Interest Coverage | −2.62 |
Quick Ratio
ENDV
Profitability
|
Metric
|
ENDV
|
|---|---|
Return on Assets (Normalized) | −315.54% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ENDV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jlhjrpddn | Sxqf | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bmmzsdtd | Wkjplh | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kgbjkqrj | Hptkyd | $99.6 Bil | |
MRNA
| Moderna Inc | Xggkfbhy | Szyd | $38.8 Bil | |
ARGX
| argenx SE ADR | Nnvbfpml | Rcqqd | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Sfkncxk | Xqx | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Djvmtxkn | Fwhyfg | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lgxgwrb | Glkdp | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Czsjqwgrh | Vbtmlhv | $12.4 Bil | |
INCY
| Incyte Corp | Xgbdgrjt | Xllnv | $11.9 Bil |